In a recent government meeting, the board approved a significant project to replace the playground at Suddlersville Elementary School, specifically designed for children aged 2 to 5 years. The contract was awarded to Game Time, a division of Cunningham Recreation, with a total cost of $349,998.37. This decision follows extensive discussions with the vendor and county parks and recreation representatives to ensure the project meets community needs.

The new playground will be constructed under the Omnia contract, which allows for streamlined procurement processes. The county's parks and recreation department will handle the demolition of the existing playground and prepare the site, which is expected to optimize the budget for new equipment. The board emphasized the importance of continuity in equipment maintenance, noting that Game Time has been a reliable vendor for over 15 years, ensuring that replacement parts are readily available.

During the meeting, board members raised questions regarding the installation costs, which amount to approximately $70,000. It was clarified that this figure covers labor for the installation of the playground and its flooring. The board also discussed the life expectancy of playgrounds, which is estimated at 20 to 25 years, and the importance of regular maintenance checks conducted by parks and recreation staff.

In addition to the playground project, the board addressed a pressing issue regarding insulin price gouging. They discussed joining a class-action lawsuit against pharmaceutical companies accused of inflating insulin prices, which can reach nearly $1,000 per vial, despite a fair market price of around $35. The board noted that participating in the lawsuit poses no financial risk to the district, as costs would only be incurred if a settlement is reached.

The meeting concluded with a motion to join the lawsuit, which was unanimously approved. The board also expressed intentions to inform the county about their decision, potentially allowing for broader participation in the legal action against the pharmaceutical companies.